Ascending Single-Dose and Multiple-Dose Study to Evaluate RJ4287 in Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

98 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-13

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Randomized Study of RJ4287 Drug to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-effect of Single and Multiple Doses in Healthy Volunteers

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JMT202

NCT06564467

Healthy Subjects

ENROLLING_BY_INVITATION PHASE1

Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects

NCT04965337

Healthy

COMPLETED PHASE1

Single Ascending Dose Study of 9MW3011 in Chinese Healthy Subject

NCT06389942

Healthy

COMPLETED PHASE1

A Clinical Study of BG136 Injection in Healthy Chinese Volunteers

NCT05984368

Healthy

UNKNOWN PHASE1

Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Administration of HS-10356 in Healthy Volunteers

NCT04652297

Healthy

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Drug Safety

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RJ4287 Tablets

single-dose or Multiple-doses, ascending dosing groups (cohorts) will be evaluated

Group Type EXPERIMENTAL

RJ4287

Intervention Type DRUG

Oral，tablets，Once daily for 14 days

Placebo

Single or multiple doses of Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Oral，tablets，Once daily daily for 14 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RJ4287

Oral，tablets，Once daily for 14 days

Intervention Type DRUG

Placebo

Oral，tablets，Once daily daily for 14 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and Female between 18 and 55 years old，inclusive
* Body weight \>50 kg for Male and \>45 kg for Female with a body mass index BMI between 19-28 kg/m2（inclusive）
* Female subjects of childbearing potential who have had no unprotected sex within 14 days prior to screening and who have had a negative pregnancy test during the screening period; subjects (including partners) who have no plans for pregnancy, sperm donation or egg donation and are willing to use effective contraception from the time of informed consent until 6 months after administration of the test product;
* The subject must be willing and able to provide written informed consent

Exclusion Criteria

* History of thyroid disorder or abnormal thyroid function tests at screening
* Abnormal abdominal ultrasound findings with clinical significance
* Subjects with any of the following laboratory tests at screening or baseline were not eligible for enrollment in this study: 1) Glutamic transaminase (AST), glutamic aminotransferase (ALT) or direct bilirubin above the upper limit of the reference range at screening; 2) Positive screening for HIV antibodies, hepatitis B surface antigen, hepatitis C antibodies, syphilis antibodies ECG QTc \> 450 ms, QRS \> 110 ms, intermittent bundle branch block, frequent premature atrial or ventricular contractions at the time of screening, or any person who is considered clinically significant by the investigator; 4) A routine blood test with a white blood cell count, neutrophil count and lymphocyte count outside the normal reference range at screening and judged clinically significant by the investigator; 5) A kidney disease diet adjustment ( MDRD) formula calculated with an estimated glomerular filtration rate (eGFR) \< 90 mL
* Sensitivity to thyroid medication or history of sensitivity to a similar study drug(eg.MGL-3196)
* History of sensitivity to a similar study drug
* Major surgical procedure, previous gastrointestinal surgery, vagotomy, bowel resection or any surgical procedure that may interfere with peristalsis, pH or absorption in the gastrointestinal tract within 6 months prior to screening
* Subjects who, in the judgement of the investigator, have a condition that affects the absorption, distribution, metabolism and excretion of the drug (e.g. gastrointestinal dysfunction, peptic ulcer, gastrointestinal surgery, etc.) or who are unable to comply with a uniform diet during the trial
* Taken any prescription medication, over-the-counter medication, any vitamin product or herbal remedy within 1 month prior to screening
* Subjects with any current or previous illness that, in the opinion of the Investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject or that could prevent, limit, or confound the protocol specified assessments or study results interpretation
* History of regular use nicotine or alcohol，unable to abstain from smoking and alcohol during the trial
* Previous blood donation or blood loss of more than 400 mL within 3 months prior to taking the study drug
* Had consumed a special diet (including popcorn, dragon fruit, mango, grapefruit, orange, etc.) or alcohol within 2 weeks before taking the study drug, or had strenuous exercise
* Taken an experimental drug or other experimental treatment within 3 months prior to screening, or being involved in any other interventional clinical trial
* Nursing female subjects
* Any other condition that, in the opinion of the investigator or sponsor, makes the subject unsuitable for inclusion in the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes